Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment

MT Newswires Live

May 01, 2025

Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.

The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with "encouraging" initial safety and electroencephalography biomarker results.

The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.

Anavex said it expects to release topline data from the study in H2.

Price: 9.37, Change: -0.13, Percent Change: -1.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2532703002"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532703002\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532703002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 23:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532703002","market":"nz","top_or_hot":-1,"title":"Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment","media":"MT Newswires Live","content":"<html><body><p> Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.</p><p>The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with \"encouraging\" initial safety and electroencephalography biomarker results.</p><p>The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.</p><p>Anavex said it expects to release topline data from the study in H2.</p><p>Price: 9.37, Change: -0.13, Percent Change: -1.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-01 23:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.</p><p>The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with \"encouraging\" initial safety and electroencephalography biomarker results.</p><p>The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.</p><p>Anavex said it expects to release topline data from the study in H2.</p><p>Price: 9.37, Change: -0.13, Percent Change: -1.37</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532703002","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532703002","pubTimestamp":1746114320,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.The company said 16","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVXL":"Anavex Life Sciences Corp."},"translate_title":"Anavex生命科学精神分裂症临床研究完成入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with \"encouraging\" initial safety and electroencephalography biomarker results.The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.Anavex said it expects to release topline data from the study in H2.Price: 9.37, Change: -0.13, Percent Change: -1.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}